Results 231 to 240 of about 186,761 (273)

Immune-Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis. [PDF]

Cancer Med
Gokhale P, Zapata LV.
europepmc   +1 more source

Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta, Tong Wang, Susmita, Ditte Marie L. Saunte, Roderick Hay, Vincent Piguet   +5 more
wiley   +1 more source

Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer. [PDF]

Curr Oncol
Vento J, Zhang T, Lotan Y, Woldu S, Qin Q.   +4 more
europepmc   +1 more source

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Journal of the European Academy of Dermatology and Venereology, EarlyView.
When questioning the effectiveness of adjuvant immunotherapy for acral melanomas, we found no clinical benefit to the adjuvant proposal, despite the maintenance of adverse effects. Abstract Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD).
Damien Sanogo, Romain Levard, Julie Cassecuel, Amir Khammari, Gaelle Quereux, Florent Grange, Henri Montaudié, Florence Brunet‐Possenti, Justine Lavaud, Marie‐Thérèse Leccia, Géraldine Jeudy, Anne Dompmartin, Brigitte Dreno, Jean‐Matthieu L’Orphelin   +13 more
wiley   +1 more source

Humanized avian embryo models replicate an immune tumor environment for rapid immunotherapy studies. [PDF]

EMBO Mol Med
Lacourrège M, Jarrosson L, Costechareyre C, Marcel M, Prunet A, Mongellaz M, Futelot C, Rouhani C, Nguyen HG, Aparicio T, Le Bourhis L, Delloye-Bourgeois C, Teinturier R, Castellani V.   +13 more
europepmc   +1 more source

Chronic rhinosinusitis during immune checkpoint inhibition in melanoma patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela, Sinja Sistani, Mareike Alter, Ralf Gutzmer   +3 more
wiley   +1 more source

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.
Glenn Geidel, Sabrina Bänsch, Laura Adam, Nathan Fekade, Alessandra Rünger, Tim Zell, Daniel J. Smit, Julian Kött, Isabel Heidrich, Michael Weichenthal, Selma Ugurel, Ulrike Leiter, Peter Mohr, Alexandra Geusau, Stephan Grabbe, Markus V. Heppt, Ralf Gutzmer, Jochen Utikal, Jan‐Christoph Simon, Sebastian Haferkamp, Laura Susok, Bastian Schilling, Edgar Dippel, Imke von Wasielewski, Jessica C. Hassel, Carola Berking, Stefan W. Schneider, Christoffer Gebhardt   +27 more
wiley   +1 more source

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775. [PDF]

J Immunother Cancer
Makker V, Colombo N, Casado A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Yonemori K, Kim YM, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kristeleit R, Nishio S, Suzuki S, Guerra Alía EM, Sanli UA, Selle F, Shikama A, Martínez Rodríguez JL, Arik Z, Arican A, Sebastianelli A, Yu Z, McKenzie J, Kruger S, Meng R, Okpara CE, Lorusso D.   +29 more
europepmc   +1 more source

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad, YuZhu Jin, Kai Luo, He Bai, Xudong Zhang, Xu Sun, Zahoor Maheen, Ali Tanveer, Saeed Muddasar Muhammad, Jialin Qu, Guixin Zhang   +10 more
wiley   +1 more source

First Successful Treatment Reported with Pembrolizumab in a Patient Diagnosed with Choriocarcinoma in Hungary. [PDF]

Life (Basel)
Lakatos KF, Kalmár L, Lahm E, Bíró EG, Fülöp V.   +4 more
europepmc   +1 more source